Drugs / BAY1082439
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01728311 | Nov 2012 → Jun 2016 | neoplasm | Bayer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY1082439 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01728311 ↗ |
| Action | Inhibit | “PI3-kinase p110-alpha subunit inhibitor” CHEMBL3644672 ↗1“PI3-kinase p110-beta subunit inhibitor” CHEMBL3644672 ↗ |
| Modality | Small molecule | — CHEMBL3644672 ↗ |
| Route | Oral | “BAY1082439 will be given orally” NCT01728311 ↗ |
| Target | PIK3CA | “PI3-kinase p110-alpha subunit inhibitor” CHEMBL3644672 ↗ |
| Target | PIK3CB | “PI3-kinase p110-beta subunit inhibitor” CHEMBL3644672 ↗ |